Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 28;9(9):1106. doi: 10.3390/biomedicines9091106

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Inhibition of ErbB3-driven proliferation of cancer cells. (a) The antiproliferative action of BCD090-P1 or BCD090-M2 on MCF-7 cells, rituximab and HeLa cells expressing negligible amounts of ErbB3 were used as negative controls; (b) the growth curves of MCF-7 cells treated with 50 μg/mL single-domain antibodies; (c) antiproliferative action of BCD090-P1, BCD090-M2 or trastuzumab on SK-BR-3 cells; (d) the viability of SK-BR-3 cells treated with a mixture of the two single-domain antibodies. The dose–response curves were fitted by the Hill equation. All data represent the mean of three replicates ± SD, p-values were calculated using t-test.